| Name | Title | Contact Details |
|---|---|---|
Norv Mcandrew |
Chief Legal Officer | Profile |
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.
LESS PAIN More Living At Southlake Orthopaedics, you can trust us to provide personalized and compassionate care, utilizing the most advanced medical technology available. Our clinics are home to the expertise of physicians in every orthopaedic special...
Trilogys Mission is to support people in their recovery from mental illness by helping them discover and reclaim their capabilities and well being.
At orthobrain®, we have reinvented the delivery of orthodontics, providing access to more people and providing dentists the opportunity to offer excellent orthodontic care to their patients. orthobrain`s consulting and education platform, powered by the expertise of Orthodontists, makes it faster, better, and easier than ever for general practitioners to deliver orthodontic care with confidence. With our system, your patients will obtain an Orthodontist-designed diagnosis, a step-by-step detailed treatment plan, and custom-made appliances from a trained dentist they already know and love - you! orthobrain makes it easy for you to start offering orthodontics in your practice immediately and transform your patients smiles for good.
Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. Nabriva was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria and commenced operations in February 2006. The new organization included small molecule assets, including pleuromutilin structure activity relationships (SAR) knowledge and was focused on synthesis of pleuromutilins for systemic human use. Following identification of our lead compound lefamulin and based on the clinical results of lefamulin for Acute Skin and Skin Structure Infections. We believed that targeted in vitro spectrum of activity for the common pathogens causing Community Acquired Bacterial Pneumonia (CABP), would allow us to develop lefamulin as the first pleuromutilin IV and oral antibiotic for human systemic administration for CABP. In 2014, we opened our US office in King of Prussia, Pennsylvania and completed an IPO on the NASDAQ under the ticker NBRV in September 2015. With net proceeds from our IPO, we initiated two global, registrational Phase 3 clinical trials of lefamulin for the treatment of moderate to severe CABP. Based on our estimates regarding patient enrollment, we expect to have top-line data available for both trials in the second half of 2017. If the results of these trials are favorable, including achievement of the primary efficacy endpoints of the trials, we expect to submit applications for marketing approval for lefamulin for the treatment of CABP in both the United States and Europe in 2018. As of April 1, 2016, Nabriva employed 52 employees at its headquarters in Vienna, Austria, and its office in King of Prussia, Pennsylvania, United States.